OncoMatch/Clinical Trials/NCT06973564
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Official title: A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 Monotherapy and in Combination With Other Agents in Adult Patients With Advanced Solid Tumors With KRAS Alteration
Is NCT06973564 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies multiple treatments including JAB-23E73 and Cetuximab for advanced solid tumors.
Treatment: JAB-23E73 · Cetuximab — This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 Monotherapy and in Combination with Other Agents in adult participants with advanced solid tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Tumor Agnostic
Colorectal Cancer
Biomarker criteria
Required: KRAS alteration
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — locally advanced or metastatic solid tumors
have received relevant prior systemic therapy.(Part A)
Must have received: systemic therapy (fluorouracil derivatives, oxaliplatin, irinotecan) — unresectable locally advanced or metastatic CRC
progressed on or were intolerant to ≥1 standard systemic regimen with fluorouracil derivatives, oxaliplatin, irinotecan, FDA-approved immunotherapy or targeted therapies.(Part B1 only)
Cannot have received: KRAS G12C inhibitor
Patients who have previously been treated with KRAS G12C inhibitors
Cannot have received: KRAS G12D inhibitor
Patients who have previously been treated with KRAS G12D inhibitors
Cannot have received: pan-RAS inhibitor
Patients who have previously been treated with pan-RAS/pan-KRAS/multi-KRAS inhibitors, or similar agents
Cannot have received: EGFR antibody (cetuximab)
Participants who have previously been treated with cetuximab or other EGFR antibodies (Part B1 only)
Lab requirements
Cardiac function
LVEF ≤50% assessed by ECHO or MUGA; QT interval>470 msec [excluded]
QT interval>470 msec. LVEF ≤50% assessed by ECHO or MUGA.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Rochester, Minnesota
- Washington University · St Louis, Missouri
- Cleveland Clinic Foundation · Cleveland, Ohio
- Huntsman Cancer Institute · Salt Lake City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06973564 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior KRAS G12C inhibitor, KRAS G12D inhibitor, pan-RAS inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS alteration is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages